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Abstract
Background:  We have recently reported that the dietary supplement Meltdown®  increases plasma
norepinephrine (NE), epinephrine (EPI), glycerol, free fatty acids (FFA), and metabolic rate in men. However, in
that investigation measurements ceased at 90 minutes post ingestion, with values for blood borne variables
peaking at this time. It was the purpose of the present investigation to extend the time course of measurement
to 6 hours, and to include women within the design to determine if sex differences to treatment exist.
Methods: Ten men (24 ± 4 yrs) and 10 women (22 ± 2 yrs) ingested Meltdown® or a placebo, using a randomized,
cross-over design with one week separating conditions. Blood samples were collected immediately before
supplementation and at one hour intervals through 6 hours post ingestion. A standard meal was provided after
the hour 3 collection. Samples were assayed for EPI, NE, glycerol, and FFA. Five minute breath samples were
collected at each time for measurement of metabolic rate and substrate utilization. Area under the curve (AUC)
was calculated. Heart rate and blood pressure were recorded at all times. Data were also analyzed using a 2 (sex)
× 2 (condition) × 7 (time) repeated measures analysis of variance, with Tukey post hoc testing.
Results: No sex × condition interactions were noted for AUC for any variable (p > 0.05). Hence, AUC data are
collapsed across men and women. AUC was greater for Meltdown® compared to placebo for EPI (367 ± 58 pg·mL-
1·6 hr-1 vs. 183 ± 27 pg·mL-1·6 hr-1; p = 0.01), NE (2345 ± 205 pg·mL-1·6 hr-1 vs. 1659 ± 184 pg·mL-1·6 hr-1; p =
0.02), glycerol (79 ± 8 μg·mL-1·6 hr-1 vs. 59 ± 6 μg·mL-1·6 hr-1; p = 0.03), FFA (2.46 ± 0.64 mmol·L-1·6 hr-1 vs. 1.57
± 0.42 mmol·L-1·6 hr-1; p = 0.05), and kilocalorie expenditure (439 ± 26 kcal·6 hrs-1 vs. 380 ± 14 kcal·6 hrs-1; p =
0.02). No effect was noted for substrate utilization (p = 0.39). Both systolic and diastolic blood pressure (p <
0.0001; 1–16 mmHg), as well as heart rate (p = 0.01; 1–9 bpm) were higher for Meltdown®. No sex × condition
× time interactions were noted for any variable (p > 0.05).
Conclusion: Ingestion of Meltdown® results in an increase in catecholamine secretion, lipolysis, and metabolic
rate in young men and women, with a similar response for both sexes. Meltdown® may prove to be an effective
intervention strategy for fat loss, assuming individuals are normotensive and their treatment is monitored by a
qualified health care professional.
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Background
The prevalence of obesity has increased to epidemic pro-
portions in recent years, with 400 million individuals
classified as obese worldwide [1,2] defined as having a
body mass index ≥ 30 kg·m-2. An additional 1.6 billion
individuals are currently classified as overweight world-
wide [2] defined as having a body mass index between 25
and 29.9 kg·m-2. Over the counter (OTC) dietary supple-
ments are often used as an aid in body fat/weight loss.
Unfortunately, many such supplements have little to no
scientific support in human subjects, while some have
been reported to cause ill-health [3]. Specifically, many
products rely exclusively on research which is conducted
using the "key ingredient" within the product of sale,
rather than the actual finished product, often at dosages
that are much higher than what is used in the actual prod-
uct of sale. Despite this shortcoming, the dietary supple-
ment market reached nearly $20 billion in United States
sales in 2007, according to the Nutrition Business Journal,
and for weight loss agents alone was estimated to be a 700
million dollar industry in 2008 [4].
Although many isolated ingredients have been shown to
have promise in relation to lipolysis, three that have been
well studied and included in many OTC dietary supple-
ments currently sold on the market include yohimbine
[5], synephrine [6], and caffeine [7]. The specific mecha-
nisms of action of these ingredients have been presented
in our recently published paper [8]. Novel variants of
these ingredients have been combined into a single die-
tary supplement (Meltdown®).
We have recently reported that the finished product Melt-
down® results in a significant increase in the area under
the curve (AUC) for blood norepinephrine (NE), glycerol,
and free fatty acids (FFA), in addition to a significant
increase in metabolic rate compared to placebo [8]. How-
ever, treatment with this agent produced an increase in
heart rate (5–6 bpm) and blood pressure (6–10 mmHg)
within the majority of subjects, which was of statistical
significance for systolic blood pressure (p = 0.04). This lat-
ter finding may be of concern for those with elevated
blood pressure. This is an important consideration in the
regular use of any dietary weight loss product, as many
contain stimulants which may promote a significant
hemodynamic response [9]. However, in this initial work,
measurements were only made for 90 minutes post inges-
tion (pre, 30 min, 60 min, 90 min), with blood values for
all variables peaking at the 90 minute post ingestion time.
These data indicate that a longer time course of measure-
ment is needed to more fully evaluate the potential lipol-
ytic effects of this dietary supplement, as well as to better
assess the hemodynamic effects of treatment. Assuming a
more prolonged effect, this agent may prove efficacious in
the treatment of obesity.
Aside from our failure to include a longer time course of
measurement, our initial work used men exclusively as
subjects. Therefore, it is presently unknown whether or
not women respond to this treatment in the same manner
as do men. It is possible that men and women may
respond differently to supplementation [10], thus gener-
alizing our initial findings in which we used men exclu-
sively as subjects [8] may be problematic. Moreover,
because many women are regular consumers of OTC die-
tary weight loss supplements, it is important to under-
stand how they would respond to such treatment.
Therefore, the purpose of the present investigation was to
extend our prior findings and to study the impact of the
lipolytic agent Meltdown®  on blood catecholamines,
markers of lipolysis, and metabolic rate in men and
women over the course of a six hour post ingestion
period, while also monitoring the hemodynamic
response to treatment.
Methods
Subjects
Healthy, exercise-trained men (n = 10) and women (n =
10) participated in this investigation. Subjects completed
a medical history and physical activity questionnaire to
determine eligibility. No subject was a smoker or had
diagnosed metabolic (including pre-diabetes or diabetes)
or cardiovascular disease. Both men and women were
considered to be exercise-trained, as they performed com-
bined aerobic and anaerobic exercise for 8 ± 3 and 8 ± 4
hrs per week, respectively, for the past several years. Sub-
ject descriptive characteristics are presented in Table 1. All
experimental procedures were performed in accordance
with the Helsinki Declaration. The University of Memphis
Human Subjects Committee approved all experimental
procedures. All subjects provided both verbal and written
consent prior to participating in this study.
Conditions and Testing
Procedures described below were identical for both test
sessions (supplement and placebo). The dietary supple-
ment used in this investigation (Meltdown®; Vital Phar-
maceuticals, Inc., Davie, FL) included yohimbine,
caffeine, and synephrine as the primary active ingredients.
Please see Figure 1 for a description of the dietary supple-
ment. Capsules were from the same bottle and produced
in accordance with Good Manufacturing Practices
(GMPs). Prior to production, all raw materials were tested
for ingredient potency and the finished product was veri-
fied for label claims. Subjects consumed the upper limit of
the recommended dosage of the dietary supplement (as
stated on the product label), which consisted of three cap-
sules, or an identical looking placebo (corn starch, micro-
crystalline cellulose, super refined sesame oil, propylene
glycol fatty acid ester, safflower oil, sunflower oil). It
should be noted that the label states that this product isLipids in Health and Disease 2009, 8:32 http://www.lipidworld.com/content/8/1/32
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"Not for use by individuals under the age of 18, by those
with a medical condition, or by pregnant or nursing
women". The experiment was conducted in a double
blind, cross-over design. Please note that due to the
potency of the dietary supplement and the fact that it con-
tains stimulants, many subjects reported that they could
"feel" an effect. Hence, the double blind nature of the
design might be considered questionable. A standard
meal replacement bar (Zero Impact®; Vital Pharmaceuti-
cals, Inc., Davie, FL) was provided to subjects after the
three hour collection period. The 112 gram bar consisted
of 440 kcal, 30 grams of protein, 35 grams of carbohy-
drate, and 20 grams of fat. Subjects were instructed to con-
sume as much of the bar as desired. Any amount not
consumed was weighed on a laboratory grade balance,
and this determined the amount of bar consumed. The
same amount was provided to subjects during their sec-
ond test session. Female subjects consumed a mean of 62
grams of the 112 gram bar, while male subjects consumed
a mean of 102 grams of the 112 gram bar. No other food
was allowed during the six hour period. However, water
was allowed ad libitum, and was measured and matched
for both days of testing (mean intake for women = 1921
mL; mean intake for men = 2163 mL).
Subjects reported to the laboratory in a fasted state (>8
hours), without caffeine consumption during the previ-
ous 8 hours. All testing was started by 1100 hours and the
time for each subject was matched for both visits. Subjects
were asked not to exercise for the 48 hours prior to each
testing day. Women reported during the first nine days of
their menstrual cycle in order to avoid any potential influ-
ence of estrogen on our chosen outcome measures. Fol-
lowing a 10 minute quiet rest period, heart rate (via
monitor) and blood pressure (via auscultation) were
measured, a blood sample was obtained, and subjects
provided a five minute breath sample (for analysis of met-
abolic rate). Subjects then ingested either the supplement
or placebo, in the presence of an investigator. At the start
of each one hour period, the same exact collection proce-
dure as described above was followed. Therefore, these
variables were collected a total of seven times for all sub-
jects (pre-ingestion, 1, 2, 3, 4, 5, 6 hours post-ingestion).
Subjects remained inactive in the laboratory during the
entire six hour test period.
Table 1: Descriptive characteristics of subjects
Variable Men
(n = 10)
Women
(n = 10)
P value
Age (yrs) 23.7 ± 4.3 21.9 ± 2.4 0.2636
Height (cm) 177.2 ± 4.7 167.4 ± 7.2 0.0019
Weight (kg) 77.4 ± 6.7 63.6 ± 11.1 0.0033
BMI (kg·m-2) 24.8 ± 2.9 22.6 ± 2.8 0.1063
Body fat (%)* 8.8 ± 3.3 23.0 ± 5.9 0.0001
Waist (cm) 81.5 ± 5.9 70.4 ± 6.2 0.0007
Hip (cm) 99.1 ± 3.0 99.4 ± 7.4 0.9225
Waist:Hip 0.82 ± 0.06 0.71 ± 0.03 0.0001
Years Anaerobic Exercise 6.2 ± 5.4 3.3 ± 3.3 0.1584
Hours per week Anaerobic Exercise 4.7 ± 2.5 3.1 ± 3.3 0.2396
Years Aerobic Exercise 3.9 ± 3.3 4.7 ± 4.0 0.6525
Hours per week Aerobic Exercise 3.1 ± 2.5 4.7 ± 3.5 0.2698
Data are mean ± SD.
* Determined from 7-site skinfold analysis use Lange calipers and Siri equation
Label description of Meltdown® Figure 1
Label description of Meltdown®.Lipids in Health and Disease 2009, 8:32 http://www.lipidworld.com/content/8/1/32
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The measurement of metabolic rate was performed using
indirect calorimetry via breath-by-breath collection (Sen-
sorMedics Vmax 229 metabolic system; Yorba Linda, CA).
All gas collection took place in a temperature and humid-
ity controlled laboratory, and both the flow sensor and
gas analyzers were calibrated prior to data collection.
Total oxygen consumption (L·min-1) was determined and
total kilocalorie expenditure was estimated from this
value. Respiratory exchange ratio (RER) was also deter-
mined from gas collection (CO2/O2), and used as a crude
measure of substrate utilization.
Blood Collection and Biochemistry
A total of seven venous blood samples (7 mL per draw)
were taken from subjects' forearm via needle and Vacu-
tainer®. Blood was immediately processed in a refrigerated
centrifuge in order to obtain plasma (4°C for 15 min at
2000 × g). Plasma samples were stored in multiple aliq-
uots at -80°C. All assays were performed on first thaw
within six weeks of sample collection. NE and EPI were
determined using an enzyme linked immunosorbent
assay (2-CAT ELISA, BA 10–1500; Rocky Mountain Diag-
nostics) following the instructions of the manufacturer
(Labor Diagnostika Nord GmbH & Co. KG). In this com-
petitive ELISA, NE and EPI are extracted by using a cis-
diol-specific affinity gel, acylated, and then derivitized
enzymatically. The coefficient of variation (CV) for NE
and EPI was 8.8% and 7.5%, respectively. Glycerol was
determined using the Free Glycerol Determination Kit
(FG0100) and Glycerol Standard (G7793), following the
instructions of the manufacturer (Sigma Aldrich). The CV
for glycerol was 7.4%. Free fatty acids were determined
using the Free Fatty Acid Quantification Kit (K612-100)
following the instructions of the manufacturer (BioVi-
sion). The CV for FFA was 8.5%.
Diet and Physical Activity
During the 24 hours before each test day, subjects con-
sumed prepackaged meal replacement drinks (protein-
rich ready-to-drink shake; Vital Pharmaceuticals, Inc.,
Davie, FL) and food bars (Zero Impact®; Vital Pharmaceu-
ticals, Inc., Davie, FL). These contained a mix of protein,
carbohydrate, and fat. Subjects were each provided with 3
shakes and 3 bars and instructed to consume as many as
they desired. No other food or calorie containing drinks
were allowed. The amount consumed during the day pre-
ceding the initial test day was mimicked during the day
preceding the second test day. The mean intake for men
was 3 shakes and 2.5 bars, while for women this was 2
shakes and 1.5 bars. These amounts provided approxi-
mately 2000 kilocalories to men and 1300 kilocalories to
women. While these amounts were estimated to be 500–
750 kilocalories lower than subjects' usual intake (based
on subjects' reports), satiety with use of these meal
replacements was reported by most subjects to be accept-
able.
Statistical Analysis
Area under the curve (AUC) was calculated for each bio-
chemical and metabolic variable for both conditions
using the trapezoidal method (AUCG) as described in
detail by Pruessner et al. [11]. Statistical comparisons for
biochemical (AUCG) and metabolic data were made using
a 2 (sex) × 2 (condition) repeated measures analysis of
variance (RMANOVA). In addition, biochemical, meta-
bolic, and hemodynamic data were also compared using
a 2 (sex) × 2 (condition) × 7 (time) RMANOVA. Tukey's
post hoc testing was used where appropriate. All analyses
were performed using JMP statistical software (version
4.0.3, SAS Institute, Cary, NC). Statistical significance was
set at P = 0.05. The data are presented as mean ± SEM,
except for subject descriptive characteristics (mean ± SD).
Results
Biochemical Data
All subjects successfully completed all aspects of the study.
Expected differences were noted between men and
women for selected anthropometric variables (Table 1).
When considering the AUC analysis, no sex × condition
interactions were noted for EPI (p = 0.57), NE (p = 0.58),
glycerol (p = 0.39), or FFA (p = 0.37). Likewise, when con-
sidering the 2 (sex) × 2 (condition) × 7 (time) RMANOVA,
no three way interactions were noted for any variable (p >
0.05). Therefore, data are presented as pooled data for
men and women in Figures 2 and 3.
Regarding the AUC main effect analyses, a condition effect
was noted for EPI (p = 0.01; Figure 2A), with no sex effect
noted (p = 0.11). The mean EPI AUC response for Melt-
down® compared to placebo was 96% for men and 91%
for women. Values increased across time with Meltdown®
and were higher at 1, 2, and 3 hours post ingestion com-
pared to pre-ingestion (p < 0.05). Both a condition (p =
0.02; Figure 2B) and sex (p = 0.01) effect was noted for
NE, with values higher for men compared to women. The
mean NE AUC response for Meltdown® compared to pla-
cebo was 44% for men and 42% for women. Values
increased across time with Meltdown® and were higher at
1 and 3 hours post ingestion compared to pre-ingestion (p
< 0.05). Both a condition (p = 0.03; Figure 3A) and sex (p
= 0.01) effect was noted for glycerol, with values higher
for women compared to men. The mean glycerol AUC
response for Meltdown® compared to placebo was 25%
for men and 42% for women. Values increased across
time with Meltdown® and were higher at 1, 2, and 3 hours
post ingestion compared to pre-ingestion (p < 0.05). Both
a condition (p = 0.05; Figure 3B) and sex (p = 0.05) effect
was noted for FFA, with values higher for women com-
pared to men. The mean FFA AUC response for Melt-Lipids in Health and Disease 2009, 8:32 http://www.lipidworld.com/content/8/1/32
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down® compared to placebo was 21% for men and 35%
for women. Values increased across time with Meltdown®
and were higher at 1 and 3 hours post ingestion compared
to pre-ingestion (p < 0.05).
Metabolic Data
When considering the AUC analysis, no sex × condition
interactions were noted for kilocalories (p = 0.27) or RER
(p = 0.87). Likewise, when considering the 2 (sex) × 2
(condition) × 7 (time) RMANOVA, no three way interac-
tions were noted (p > 0.05). Therefore, data are presented
as pooled data for men and women in Figure 4. Regarding
the AUC main effect analyses, both a condition (p = 0.02;
Figure 4A) and sex (p < 0.001) effect was noted for kilo-
calorie expenditure, with values higher for men compared
to women. The mean kilocalorie AUC response for Melt-
down® compared to placebo was 19% for men and 13%
for women. Values increased across time with Meltdown®
and were higher at 1, 2, 3, 4, and 5 hours post ingestion
compared to pre-ingestion (p < 0.05). Neither a condition
Plasma epinephrine (A) and norepinephrine (B) data for men  and women consuming Meltdown® and placebo in a rand- omized cross-over design Figure 2
Plasma epinephrine (A) and norepinephrine (B) data 
for men and women consuming Meltdown® and pla-
cebo in a randomized cross-over design. Data are mean 
± SEM. * Greater epinephrine (367 ± 58 pg·mL-1·6 hr-1 vs. 
183 ± 27 pg·mL-1·6 hr-1; p = 0.01) and norepinephrine (2345 
± 205 pg·mL-1·6 hr-1 vs. 1659 ± 184 pg·mL-1·6 hr-1; p = 0.02) 
AUC for Meltdown® compared to placebo.
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Plasma glycerol (A) and free fatty acid (B) data for men and  women consuming Meltdown® and placebo in a randomized  cross-over design Figure 3
Plasma glycerol (A) and free fatty acid (B) data for 
men and women consuming Meltdown® and placebo 
in a randomized cross-over design. Data are mean ± 
SEM. * Greater glycerol (79 ± 8 μg·mL-1·6 hr-1 vs. 59 ± 6 
μg·mL-1·6 hr-1; p = 0.03), and FFA (2.46 ± 0.64 mmol·L-1·6 hr-
1 vs. 1.57 ± 0.42 mmol·L-1·6 hr-1; p = 0.05) AUC for Melt-
down® compared to placebo.
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(p = 0.39; Figure 4B) nor a sex (p < 0.53) effect was noted
for RER.
Hemodynamic Data
No three way interactions were noted for heart rate, systo-
lic or diastolic blood pressure (p > 0.05). A condition
effect was noted for heart rate (p = 0.01), with values
higher with Meltdown® compared to placebo. No other
effects were noted for heart rate (p > 0.05). A condition ×
time (p = 0.03) and sex (p < 0.0001) effect was noted for
systolic blood pressure, with values higher with Melt-
down®  across time, and higher for men compared to
women. As with systolic blood pressure, a condition ×
time (p = 0.05) and sex (p < 0.0001) effect was noted for
diastolic blood pressure, with values higher with Melt-
down®  across time, and higher for men compared to
women. Hemodynamic data are presented in Table 2.
Discussion
Our data indicate that the OTC dietary supplement Melt-
down®, ingested at the exact dosage as recommended by
the manufacturer, results in an increase in plasma EPI, NE,
glycerol and FFA, as well as an increase in metabolic rate.
The increase for all variables is most robust during the ini-
tial three hours following ingestion (prior to food intake),
but the metabolic rate remains elevated in a statistically
significant manner above pre-ingestion values during the
five hour post ingestion period. The overall response for
our outcome measures is similar for both men and
women. An increase in heart rate (ranging from 1–9
bpm), systolic (ranging from 5–16 mmHg), and diastolic
(ranging from 1–10 mmHg) blood pressure is also noted
with treatment, highlighting the need for careful consider-
ation of use of this agent for those individuals who are
hypertensive (blood pressure ≥ 140/90 mmHg) or who
may be pre-hypertensive (blood pressure 120–139/80–89
mmHg). For such individuals, it would be best to attempt
weight/fat loss through both increased physical activity
and modified dietary intake. Once a stable weight is main-
tained and the individual has a blood pressure value
within desired limits, they may consider using such an
agent in an attempt for further weight/fat loss. As with any
weight/fat loss aid that impacts catecholamine secretion,
it is prudent for individuals to be monitored by a qualified
health care provider during the course of use.
The current data extend our initial findings in which we
noted an increase in plasma EPI, NE, glycerol, FFA, and
metabolic rate in a sample of exercise-trained men [8]. In
that original investigation of Meltdown®, measurements
were only carried out for 90 minutes post ingestion, with
values for blood borne variables peaking at the 90 minute
post ingestion time. The present study provides additional
support for the lipolytic effects of this agent, demonstrat-
ing that the effects are longer lasting. However, despite rel-
atively high values at the hour three measurement time,
values were drastically reduced following intake of food
(Figures 2 and 3). This clearly demonstrates the effect of
feeding on blunting the catecholamine response, and sub-
sequent lipolysis, associated with lipolytic agents such as
Meltdown®.
Our findings are similar for both men and women. Hence,
both sexes may benefit from use of this agent. While data
from our acute studies appear to indicate a potential ben-
Kilocalories (A) and respiratory exchange ratio (B) data for  men and women consuming Meltdown® and placebo in a ran- domized cross-over design Figure 4
Kilocalories (A) and respiratory exchange ratio (B) 
data for men and women consuming Meltdown® and 
placebo in a randomized cross-over design. Data are 
mean ± SEM. * Greater kilocalories (439 ± 26 kcal·6 hrs-1 vs. 
380 ± 14 kcal·6 hrs-1; p = 0.02) for Meltdown® compared to 
placebo.
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efit of this agent on weight/fat loss over time, and anecdo-
tal reports suggest this to be the case, we must admit that
no controlled scientific investigations have been con-
ducted testing the chronic effect of this agent on body
weight/fat loss, in addition to other important metabolic
and biochemical variables associated with obesity (e.g.,
blood lipids, inflammatory biomarkers, oxidative stress
biomarkers, etc.). Future intervention studies are needed
to provide evidence pertaining to these outcome meas-
ures.
Although we are not certain as to which of the active ingre-
dients contained within Meltdown® are actually responsi-
ble for the observed effects, we believe that our findings
can be largely attributed to the three primary active ingre-
dients yohimbine, caffeine, and synephrine. Fatty acid
oxidation involves the complex interaction between hor-
mone sensitive lipase (HSL), hormones acting to stimu-
late HSL, and the receptors that bind these hormones in
order for them to exert their effect [12]. While hormones
such as growth hormone, thyroid hormone, ACTH, and
cortisol all appear involved in lipolysis, the catecho-
lamines EPI and NE appear most important [12], as these
interact with both beta adrenergic receptors (EPI and NE),
as well as alpha-adrenergic receptors (NE). Although HSL
is stimulated by the increase in EPI and NE, it is the initial
binding of the EPI and NE to beta receptors that begins the
secondary intracellular activation of adenylyl cyclase [13].
This results in an increased production of cAMP [14],
which leads to the activation of a cAMP dependent pro-
tein kinase (PKA) [15]. It is PKA that then activates HSL
leading to triglyceride breakdown and subsequent release
of glycerol and FFA into the circulation. This was clearly
demonstrated in Figure 3. It appears that NE may have the
greatest effect on lipolysis [16], which may occur not only
via activation of HSL, but through HSL translocation from
the cytosol to the lipid droplets in fat cells [17]. Our data
support this notion, as the percent increase in NE was
more similar to both glycerol and FFA than was the per-
cent increase in EPI (Figures 2 and 3).
Yohimbine itself has been reported in several studies to
increase blood NE [18-21], as well as EPI [21,22]. This was
clearly demonstrated in the present investigation (Figure
2). This was observed despite the relatively low dosage of
yohimbine provided within the supplement (9 mg) com-
pared to other studies using dosages equal to 2–5 times
this amount [18-21]. The form of yohimbine used in the
Table 2: Hemodynamic data for men and women consuming Meltdown® and placebo in a randomized cross-over design.
Variable Sex Pre 1 hr 2 hr 3 hr 4 hr 5 hr 6 hr
HR (bpm)
Meltdown®
Men 54 ± 3 54 ± 3 62 ± 7 59 ± 4 63 ± 4 62 ± 3 60 ± 2
HR (bpm)
Placebo
Men 56 ± 4 53 ± 3 53 ± 3 51 ± 3 60 ± 2 57 ± 2 54 ± 3
HR (bpm)
Meltdown®
Women 61 ± 4 56 ± 3 61 ± 4 61 ± 4 61 ± 3 65 ± 6 59 ± 3
HR (bpm)
Placebo
Women 62 ± 4 57 ± 3 56 ± 4 57 ± 4 59 ± 4 59 ± 4 56 ± 3
SBP (mmHg)
Meltdown®
Men 118 ± 2 128 ± 3 131 ± 5 132 ± 4 131 ± 3 128 ± 3 126 ± 3
SBP (mmHg)
Placebo
Men 117 ± 3 117 ± 4 115 ± 2 116 ± 3 123 ± 2 117 ± 2 117 ± 3
SBP (mmHg)
Meltdown®
Women 104 ± 3 110 ± 2 114 ± 3 116 ± 3 112 ± 3 109 ± 2 109 ± 2
SBP (mmHg)
Placebo
Women 104 ± 2 103 ± 2 107 ± 3 105 ± 2 107 ± 2 102 ± 2 104 ± 2
DBP (mmHg)
Meltdown®
Men 74 ± 2 74 ± 2 74 ± 2 78 ± 2 71 ± 3 74 ± 3 72 ± 3
DBP (mmHg)
Placebo
Men 69 ± 2 71 ± 2 69 ± 2 68 ± 2 67 ± 2 65 ± 2 67 ± 2
DBP (mmHg)
Meltdown®
Women 64 ± 2 68 ± 2 71 ± 2 71 ± 2 66 ± 2 69 ± 1 69 ± 2
DBP (mmHg)
Placebo
Women 69 ± 2 68 ± 2 68 ± 2 66 ± 2 65 ± 2 61 ± 2 63 ± 2
Data are mean ± SEM.
Condition effect for heart rate (p = 0.01); Condition × time (p = 0.03) and sex (p < 0.0001) effect for systolic blood pressure; Condition × time (p 
= 0.05) and sex (p < 0.0001) effect for diastolic blood pressure.
HR-heart rate; SBP-systolic blood pressure; DBP-diastolic blood pressureLipids in Health and Disease 2009, 8:32 http://www.lipidworld.com/content/8/1/32
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supplement could be responsible for the observed
increase in EPI and NE, as a combination of yohimbine
HCl, alpha-yohimbine, and 11-hydroxy yohimbine make
up the total yohimbine complex provided in Meltdown®.
Caffeine has lipolytic and thermogenic effects due to its
ability to lessen the degradation of cAMP as well as
increase cAMP production via beta-adrenergic receptor
independent and dependent mechanisms, respectively
[23]. The independent effects appear due to caffeine's
ability to directly inhibit cAMP degradation, by inhibiting
the cyclic nucleotide phosphodiesterase [24] and blocking
adenosine receptors. The direct effect results from an
increase in catecholamine release following caffeine
ingestion, which may be secondary to the previously
described adenosine inhibition [23]. Synephrine also
interacts with beta receptors (3 sub-class) and promotes
lipolysis via the above described cAMP dependent mech-
anism [25].
Several other ingredients are included within Meltdown®
including the amphetamine-like/thyroid stimulating
agent phenylethylamine (PEA), which is known to stimu-
late a rise in blood catecholamine levels and inhibiting
their reuptake [26]. The monoamine oxidase inhibitor
methyl hordinine is also contained within this supple-
ment. Hordinine is structurally similar to EPI and has
been shown to liberate NE from its storage site, in addi-
tion to inhibiting NE metabolism [27]. Methyl tetrade-
cylthioacetic acid is also included, and known to
stimulate beta oxidation [28] and to be involved in lipid
transport and utilization [29].
Collectively, the above ingredients appear to represent a
substantial list of potentially effective lipolytic agents. Our
data indicate that during an acute monitoring period,
Meltdown® effectively stimulates catecholamine secretion,
lipolysis, and metabolic rate, and does so in both men
and women. Two other studies using Meltdown®, while
not measuring blood catecholamine levels and markers of
lipolysis, support our findings of increased metabolic rate
both at rest [30,31] and in response to acute aerobic exer-
cise [31].
Conclusion
In conclusion, we report that the finished product Melt-
down®, ingested at the recommended dosage by young
and healthy men and women, results in an increase in
plasma EPI, NE, glycerol, and FFA, in addition to meta-
bolic rate. This occurs primarily over the initial three hour
period following ingestion; however the effects for kilo-
calorie expenditure are maintained for five hours post
ingestion. An increase in both heart rate and blood pres-
sure are also observed during these times, which may be
of concern to some individuals, in particular those with
elevated resting blood pressure. Whether or not the lipol-
ytic effects are maintained with chronic intake remains to
be determined, as most individuals experience some
desensitization with chronic treatment, which often
requires a higher dosage in order to maintain effective-
ness. Moreover, due to the potent metabolic effects of
such dietary agents, it is possible that individuals who
cease use after chronic intake may experience a lower rest-
ing metabolic rate as a result. Future research is needed to
address these issues. While anecdotal evidence indicates
that Meltdown® continues to exhibit potent effects on
weight loss despite intake over periods of several weeks of
use, well-controlled clinical trials are indeed needed to
confirm this. Such studies may seek to determine the
chronic effects of Meltdown® on body weight/fat loss and
associated metabolic and biochemical markers of health.
Favorable findings could lead to recommendations for the
inclusion of this supplement in the weight/fat loss arsenal
of those classified as obese.
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